右美托咪定联合艾司氯胺酮预防腹腔镜手术患者术后恶心呕吐:一项前瞻性随机对照试验的研究方案
联合组诱导给予右美托咪定0.5 μg/kg、艾司氯胺酮0.3 mg/kg、舒芬太尼0.2 μg/kg和丙泊酚1.5-2.0 mg/kg,对照组诱导给予舒芬太尼0.5 μg/kg和丙泊酚1.5-2.0 mg/kg,主要结局为术后48小时内术后恶心呕吐(PONV)发生率。
要点
- 主要结局为术后48小时内PONV发生率,分0-6小时、6-24小时、24-48小时三个时段评估。
- 联合组诱导加用右美托咪定0.5 μg/kg与艾司氯胺酮0.3 mg/kg,对照组维持加用瑞芬太尼0.1 μg/kg/min。
- 研究旨在评估该联合策略预防PONV的安全性与可行性,为减少阿片类药物的麻醉策略提供证据。
核心结论
- 本研究旨在评估右美托咪定联合艾司氯胺酮预防腹腔镜手术患者PONV的安全性与可行性,研究结果可能为一种有效的减少阿片类药物的麻醉策略提供证据。
关键数值与推荐
- 联合组诱导给予右美托咪定0.5 μg/kg、艾司氯胺酮0.3 mg/kg、舒芬太尼0.2 μg/kg和丙泊酚1.5-2.0 mg/kg,术中维持使用七氟烷2-3%。
- 对照组诱导给予舒芬太尼0.5 μg/kg和丙泊酚1.5-2.0 mg/kg,术中维持使用七氟烷2-3%吸入及瑞芬太尼0.1 μg/kg/min持续输注。
- 主要结局为术后48小时内PONV发生率,分0-6小时、6-24小时、24-48小时三个时段评估。
- 次要结局包括Apfel PONV风险评分、术后0、6、12、24、48小时疼痛评分、首次PONV及首次补救止吐时间、首次补救镇痛时间、48小时内补救镇痛药和止吐药总剂量与频次、出院时患者满意度评分、住院时长、出院状况及不良事件发生率和分类。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Laparoscopic surgery has gained widespread acceptance due to its advantages over traditional open procedures, including less postoperative pain and faster recovery. However, postoperative nausea and vomiting (PONV) remains a prevalent complication, affecting up to 80% of high-risk patients and significantly reducing patient satisfaction and recovery quality. Although opioids are frequently used for intraoperative analgesia, their side effects, particularly PONV, highlight the need for opioid-sparing strategies. Dexmedetomidine and esketamine are two agents with analgesic and anesthetic-sparing properties that have shown promise individually in reducing PONV and postoperative pain. However, evidence remains limited, and no study has systematically evaluated the combined use of dexmedetomidine and esketamine for PONV prevention in laparoscopic surgery. This trial aims to fill this knowledge gap by assessing the efficacy and safety of this novel combination strategy, potentially offering an improved anesthetic regimen for enhanced postoperative recovery. METHODS: To address this gap, we propose a prospective, randomized, controlled trial (RCT) at a single center to evaluate the effects of dexmedetomidine and esketamine on PONV in laparoscopic surgery patients. Patients will be randomly assigned to either the combination therapy group or the control group in a 1:1 ratio. The combination therapy group (n = 70) will receive intravenous dexmedetomidine (0.5 μg/kg), esketamine (0.3 mg/kg), sufentanil (0.2 μg/kg) and propofol (1.5-2.0 mg/kg) for anesthesia induction, with sevoflurane (2-3%) used for maintenance during surgery. Conversely, the control group (n = 70) will receive sufentanil (0.5 μg/kg) and propofol (1.5-2.0 mg/kg) for anesthesia induction, followed by sevoflurane (2-3%) inhalation and continuous remifentanil infusion (0.1 μg/kg/min) for maintenance. The primary outcome is the incidence of PONV within 48 h postoperatively, assessed during three predefined intervals: 0-6 h, 6-24 h, and 24-48 h. Secondary outcomes include Apfel PONV risk score, pain scores at 0, 6, 12, 24, and 48 h postoperatively, time to first PONV episode and first rescue antiemetic, time to first rescue analgesic, total dosage and frequency of rescue analgesics and antiemetics within 48 h, patient satisfaction score at discharge, length of hospital stay, discharge condition, and the incidence and classification of adverse events. DISCUSSSION: This study aims to evaluate the safety and feasibility of combining dexmedetomidine and esketamine to prevent PONV in patients undergoing laparoscopic surgery. The findings may offer evidence for an effective opioid-reducing anesthesia strategy that enhances analgesia and supports recovery, with potential value for broader clinical application. TRIAL REGISTRATION {2A,2B}: Chinese Clinical Trial Register, ChiCTR2300072455. Registered on June 14, 2023.
引用
- Zhou Y, Shen Z, Li J, et al. Combination of dexmedetomidine and esketamine for postoperative nausea and vomiting in patients undergoing laparoscopic surgery: study protocol for a prospective, randomized, controlled trial. Trials. 2025. PMID: 40598630. doi:10.1186/s13063-025-08935-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。